Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Results A total of 108 patients (mean [SD] age, 74.8 [5.9] years; 67 men [62%]) were included in the intention-to-treat analysis, with 54 randomized to receive bupropion and 54 randomized to receive placebo. After controlling for the baseline AES-C score, site, and comedication with donepezil or galantamine, the mean change in the AES-C score between the bupropion and placebo groups was not statistically significant (mean change, 2.22; 95% CI, -0.47 to 4.91; P = .11). Results on secondary outcomes showed statistically significant differences between bupropion and placebo in terms of total neuropsychiatric symptoms (mean change, 5.52; 95% CI, 2.00 to 9.04; P = .003) and health-related quality of life (uncorrected for multiple comparisons; mean change, -1.66; 95% CI, -3.01 to -0.31; P = .02) with greater improvement in the placebo group. No statistically significant changes between groups were found for activities of daily living (mean change, -2.92; 95% CI, -5.89 to 0.06; P = .05) and cognition (mean change, -0.27; 95% CI, -3.26 to 2.73; P = .86).

What this study adds

Evidence grade: High

This is a trial of 108 participants. In this trial of 108 patients, bupropion did not significantly reduce apathy compared with placebo in people with Alzheimer's disease. Reported effect size: 72.2%; 61.1%; 9.3%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Maier, F., Spottke, A., Bach, J. P., Bartels, C., Buerger, K., Dodel, R., et al. (2020). Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2020.6027

Vancouver

Maier F, Spottke A, Bach JP, Bartels C, Buerger K, Dodel R, et al. Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial. JAMA network open. 2020. doi:10.1001/jamanetworkopen.2020.6027. PMID: 32463470.

BibTeX

@article{maier2020-32463470,
  author  = {Maier, F. and Spottke, A. and Bach, J. P. and Bartels, C. and Buerger, K. and Dodel, R. and Fellgiebel, A. and Fliessbach, K. and others},
  title   = {{Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA network open},
  year    = {2020},
  doi     = {10.1001/jamanetworkopen.2020.6027},
  pmid    = {32463470},
  url     = {https://doi.org/10.1001/jamanetworkopen.2020.6027}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this trial of 108 patients, bupropion did not significantly reduce apathy compared with placebo in people with Alzheimer's disease. On secondary outcomes, the placebo group showed greater improvement in total neuropsychiatric symptoms and health-related quality of life.

Study details

How this study scored 71/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 71 of 100.71 of 100 points earned29 not earned

Published in a leading specialty journal, and it is a randomized controlled trial.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA network open)
Journal's citation record 2 / 4 JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 2 / 4 108 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 4 / 7 Cited 44 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.5 citations a year over 8 year(s) since 2020
Impact for its field and year 3 / 6 Cited 3.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Frank Jessen: h-index 101 (OpenAlex, whole career)
Institution's track record 1 / 3 Heidelberg University: institution h-index 1,344 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 24 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32463470)
Free to read 2 / 2 Free to read
Total 71 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →